{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:25:10Z","timestamp":1773811510178,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017301","name":"Forest Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jash.2012.02.002","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T10:38:10Z","timestamp":1331894290000},"page":"228-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial"],"prefix":"10.1016","volume":"6","author":[{"given":"Andrew","family":"Lewin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Lasseter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2012.02.002_bib1","doi-asserted-by":"crossref","first-page":"26F","DOI":"10.1016\/0002-9149(87)90038-5","article-title":"Beta-adrenergic blocker withdrawal","volume":"59","author":"Frishman","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2012.02.002_bib2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1742-1241.2005.00523.x","article-title":"Consequences of the discontinuation of antihypertensive treatment in successfully treated patients","volume":"59","author":"Charalabopoulos","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jash.2012.02.002_bib3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0140-6736(79)90976-0","article-title":"Beta-blocker withdrawal syndrome?","volume":"1","author":"Kristensen","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2012.02.002_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(73)90235-3","article-title":"Withdrawal of propranolol and myocardial infarction","volume":"1","author":"Slome","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2012.02.002_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1368-5031.2005.00520.x","article-title":"Withdrawal syndrome following cessation of antihypertensive drug therapy","volume":"59","author":"Karachalios","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jash.2012.02.002_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","article-title":"Nebivolol: the somewhat-different beta-adrenergic receptor blocker","volume":"54","author":"M\u00fcnzel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2012.02.002_bib7","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/clc.20508","article-title":"Nebivolol efficacy and safety in patients with stage I-II hypertension","volume":"33","author":"Greathouse","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jash.2012.02.002_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","article-title":"The efficacy and tolerability of nebivolol in hypertensive African American patients","volume":"9","author":"Saunders","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2012.02.002_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1524-6175.2007.06679.x","article-title":"A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension","volume":"9","author":"Weiss","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2012.02.002_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/jhh.2009.33","article-title":"Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension","volume":"24","author":"Neutel","year":"2009","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2012.02.002_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1000392","article-title":"A dose-response trial of nebivolol in essential hypertension","volume":"11","author":"Van Nueten","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2012.02.002_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.jhh.1000571","article-title":"Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial","volume":"12","author":"Van Nueten","year":"1998","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2012.02.002_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00151642-200512010-00005","article-title":"Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective \u03b2-blockers in the treatment of hypertension: a meta-analysis","volume":"12","author":"Ambrosioni","year":"2005","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.jash.2012.02.002_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","article-title":"Effects\u00a0of\u00a0antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis","volume":"375","author":"Webb","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2012.02.002_bib15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cpt1978236624","article-title":"Propranolol withdrawal and thyroid hormones in patients with essential hypertension","volume":"23","author":"Kristensen","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jash.2012.02.002_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/clpt.1982.2","article-title":"Metoprolol withdrawal phenomena: mechanism and prevention","volume":"31","author":"Rangno","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jash.2012.02.002_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/0002-9149(82)91965-8","article-title":"Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule","volume":"49","author":"Rangno","year":"1982","journal-title":"Am J Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.jash.2012.02.002_bib18","first-page":"35","article-title":"The beta-adrenergic blockade withdrawal phenomenon","volume":"14","author":"Walden","year":"1983","journal-title":"J Pharmacol"},{"key":"10.1016\/j.jash.2012.02.002_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00563108","article-title":"Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin","volume":"15","author":"Lederballe Pedersen","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.jash.2012.02.002_bib20","first-page":"345S","article-title":"Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol","volume":"13","author":"Rangno","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jash.2012.02.002_bib21","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/01.CIR.59.6.1158","article-title":"Mechanism of propranolol withdrawal phenomena","volume":"59","author":"Nattel","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2012.02.002_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0140-6736(79)90976-0","article-title":"Beta-blocker withdrawal syndrome?","volume":"1","author":"Kristensen","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2012.02.002_bib23","series-title":"Bystolic: Full Prescribing Information","year":"2010"},{"key":"10.1016\/j.jash.2012.02.002_bib24","series-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Goodman","year":"2001"},{"key":"10.1016\/j.jash.2012.02.002_bib25","unstructured":"Corgard (nadolol) Tablet - prescribing information [Internet database]. Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=6851. Accessed Jan. 18,\u00a02011."},{"issue":"Suppl 3","key":"10.1016\/j.jash.2012.02.002_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2007.06633.x","article-title":"A historical perspective on the development of \u03b2-adrenergic blockers","volume":"9","author":"Frishman","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jash.2012.02.002_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0002-8703(90)90013-N","article-title":"Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences","volume":"120","author":"Krukemyer","year":"1990","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2012.02.002_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1476-5381.1988.tb11576.x","article-title":"Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment","volume":"94","author":"Michel","year":"1988","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jash.2012.02.002_bib29","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/hc4301.098282","article-title":"Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity","volume":"104","author":"Azevedo","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2012.02.002_bib30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0022-3565(24)34948-1","article-title":"Mechanism-based modeling of rebound tachycardia after chronic l-propranolol infusion in spontaneous hypertensive rats","volume":"290","author":"Brynne","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jash.2012.02.002_bib31","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1523\/JNEUROSCI.1667-10.2010","article-title":"Beta-adrenoceptor blockers increase cardiac sympathetic innervation by inhibiting autoreceptor suppression of axon growth","volume":"30","author":"Clarke","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.jash.2012.02.002_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0002-9149(03)00645-3","article-title":"Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension","volume":"92","author":"Kamp","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171112000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171112000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:31:24Z","timestamp":1761831084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171112000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1933171112000617"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2012.02.002","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2012.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}